A GLP-1, GIP and glucagon receptor agonist — often called a triple agonist or “triagonist” — is a single engineered molecule that activates three receptors at once: the two incretin receptors (GLP-1 and GIP) plus the glucagon receptor. It represents the next step beyond dual incretin agonists, adding a third metabolic pathway to the combination. The leading example is retatrutide. The addition of glucagon receptor activity may seem counterintuitive — glucagon is best known for raising blood glucose — but in the context of a triple agonist it is included for its effects on energy expenditure and hepatic metabolism. This guide explains what each of the three receptors contributes, why glucagon is added despite its glucose-raising reputation, and how the triple-agonist concept works.
The three receptors at a glance
| Receptor | Mimics | Primary documented contribution |
|---|---|---|
| GLP-1 receptor | GLP-1 (incretin) | Glucose-dependent insulin secretion, glucagon suppression, appetite signalling |
| GIP receptor | GIP (incretin) | Glucose-dependent insulin secretion, lipid metabolism |
| Glucagon receptor | Glucagon | Energy expenditure, hepatic metabolism |
| Triple agonist example | Retatrutide (all three) | |
Trutide supplies research-grade Retatrutide — a GLP-1, GIP and glucagon receptor triple agonist — at ≥98% HPLC purity, independently tested by Janoshik Analytical.
Building on the incretin foundation
The triple agonist builds directly on the dual incretin agonist concept. The two incretin receptors — GLP-1 and GIP — both enhance glucose-dependent insulin secretion, and combining them is the basis of dual agonists like tirzepatide. The GLP-1 receptor also suppresses glucagon, slows gastric emptying, and influences appetite; the GIP receptor adds effects on lipid metabolism. For a full treatment of how these two incretin pathways work and why they are combined, see our guide on GLP-1 and GIP dual agonists.
The triple agonist takes this established incretin combination and adds a third receptor target: the glucagon receptor. Everything the dual incretin combination does is retained; the glucagon activity is layered on top. The interesting question — and the focus of this guide — is what that third receptor contributes and why it is included.
The glucagon paradox
At first glance, adding glucagon receptor activity to a metabolic compound seems contradictory. Glucagon is the hormone that raises blood glucose — it signals the liver to release stored glucose, opposing the action of insulin. Why would a compound aimed at metabolic research include activity at the receptor for a glucose-raising hormone?
The answer lies in glucagon’s other documented effects, which extend well beyond its role in glucose release. Glucagon receptor activation has documented effects on energy expenditure — it can increase metabolic rate and energy consumption — and on hepatic lipid metabolism, where it influences the processing of fats in the liver. In the context of a triple agonist, these effects are the reason for including glucagon activity.
The glucose-raising tendency of glucagon is, in the triple-agonist design, counterbalanced by the strong incretin activity of the GLP-1 and GIP components, which enhance glucose-dependent insulin secretion and (in the case of GLP-1) suppress glucagon’s glucose-raising signalling. The design intent is to harness glucagon’s energy-expenditure and hepatic-metabolism effects while the incretin components manage glucose control. The result is a balance of three pathways that the dual incretin combination cannot replicate.
What each receptor contributes to the triple combination
GLP-1 receptor
Provides glucose-dependent insulin secretion, suppression of glucagon’s glucose-raising signal, slowed gastric emptying, and appetite signalling through central pathways. It is the most broadly active of the three and the foundation of the incretin effect.
GIP receptor
Adds further glucose-dependent insulin secretion alongside documented roles in lipid metabolism and adipose tissue signalling. It complements GLP-1 on the shared insulin endpoint while engaging metabolic pathways GLP-1 does not.
Glucagon receptor
Adds energy-expenditure and hepatic-metabolism effects — the dimension that distinguishes a triple agonist from a dual incretin agonist. This is the pathway the incretin combination cannot reach, and the reason the third receptor is included despite glucagon’s glucose-raising reputation.
The triple-agonist concept and balance
Designing a triple agonist is more complex than simply combining three activities. The relative potency at each of the three receptors — the balance between GLP-1, GIP, and glucagon activity — is a critical design parameter. Too much glucagon activity relative to the incretin components could tip the glucose balance unfavourably; too little would forgo the energy-expenditure benefit that motivates including glucagon at all. A triple agonist is therefore engineered to a specific ratio of activities at the three receptors, tuned so that the incretin components keep glucose control while the glucagon component contributes its metabolic effects.
Retatrutide is the leading example of this triple-agonist class. Like other peptides in this family it is acylated with a fatty acid chain to bind albumin and resist DPP-4 degradation, supporting an extended half-life suitable for once-weekly administration in research protocols. For a full overview of retatrutide specifically, see our Retatrutide research guide.
Dual vs triple agonists
The progression from dual to triple agonists reflects an expanding set of metabolic targets.
| Type | Receptors | Example | Adds |
|---|---|---|---|
| GLP-1 agonist | GLP-1 | (single-target agonists) | Incretin foundation |
| Dual agonist | GLP-1 + GIP | Tirzepatide | GIP lipid/metabolic pathway |
| Triple agonist | GLP-1 + GIP + glucagon | Retatrutide | Glucagon energy-expenditure pathway |
Each step adds a pathway rather than replacing one. The dual agonist adds GIP to GLP-1; the triple agonist adds glucagon on top of both. For the detail on the GLP-1/GIP incretin foundation, see our guide on GLP-1 and GIP dual agonists.
Frequently asked questions
What is a GLP-1, GIP and glucagon triple agonist?
It is a single engineered peptide that activates three receptors at once: the two incretin receptors (GLP-1 and GIP) plus the glucagon receptor. Retatrutide is the leading example. It builds on the dual incretin agonist concept by adding a third metabolic pathway.
Why add glucagon when glucagon raises blood sugar?
Glucagon has documented effects beyond raising glucose — particularly on energy expenditure and hepatic lipid metabolism. In a triple agonist, these effects are the reason for including it. Its glucose-raising tendency is counterbalanced by the strong incretin activity of the GLP-1 and GIP components, which enhance glucose-dependent insulin secretion and suppress glucagon’s glucose signal.
How is a triple agonist different from a dual agonist?
A dual agonist (e.g. tirzepatide) activates the two incretin receptors, GLP-1 and GIP. A triple agonist (e.g. retatrutide) adds a third target, the glucagon receptor, contributing energy-expenditure and hepatic-metabolism effects that the incretin combination alone does not reach.
What does the glucagon receptor contribute?
Energy expenditure and hepatic lipid metabolism. These are the effects that distinguish a triple agonist from a dual incretin agonist, and the reason the glucagon receptor is included despite glucagon’s role in glucose release.
Why does receptor balance matter in a triple agonist?
The relative potency at each receptor is a critical design parameter. The incretin components must be strong enough to maintain glucose control against glucagon’s glucose-raising tendency, while the glucagon component must be sufficient to contribute its energy-expenditure effects. A triple agonist is engineered to a specific tuned ratio of the three activities.
Which is the leading triple agonist?
Retatrutide is the leading GLP-1/GIP/glucagon triple agonist. It is acylated for an extended half-life supporting once-weekly administration in research protocols.
Can triple agonists be used in humans?
No. Retatrutide supplied by Trutide is intended strictly for in vitro laboratory and scientific research. It is not for human or veterinary consumption, clinical use, or self-administration.
Further reading
For a full overview of the leading triple agonist — including mechanism, pharmacokinetics, published research, and handling — see our Retatrutide research guide. For the incretin foundation the triple agonist builds on, see our guide on GLP-1 and GIP dual agonists.
Trutide supplies research-grade Retatrutide at ≥98% HPLC purity, independently tested by Janoshik Analytical. You will also need bacteriostatic water for reconstitution.
Research use only. This article is intended for qualified researchers only. All information is provided for educational and scientific reference purposes. Nothing in this article constitutes medical advice. Retatrutide supplied by Trutide is strictly for in vitro laboratory research and is not for human or veterinary use.
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism. 2018;20(Suppl 1):5-21. doi:10.1111/dom.13129
- Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The new biology and pharmacology of glucagon. Physiological Reviews. 2017;97(2):721-766. doi:10.1152/physrev.00025.2016
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine. 2015;21(1):27-36. doi:10.1038/nm.3761
Last updated: 7 June 2026